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Glucagon-likepeptide-1 (GLP-1) and itsanalogsact as
appetite suppressants and have been proven to be
clinically efficacious in reducing body weight in obese
individuals.CentralGLP-1 is expressed in a small pop-
ulationofbrainstemcells located in thenucleus tractus
solitarius (NTS), which project to a wide range of brain
areas. However, it remains unclear how endogenous
GLP-1 released in the brain contributes to appetite
regulation. Using chemogenetic tools, we discovered
that central GLP-1 acts on the midbrain ventral
tegmental area (VTA) and suppresses high-fat food
intake. We used integrated pathway tracing and syn-
aptic physiology to further demonstrate that activation
of GLP-1 receptors specifically reduces the excitatory
synaptic strength of dopamine (DA) neuronswithin the
VTA that project to the nucleus accumbens (NAc)
medial shell. These data suggest that GLP-1 released
from NTS neurons can reduce highly palatable food
intake by suppressing mesolimbic DA signaling.
INTRODUCTION
The central glucagon-like peptide-1 (GLP-1) system plays a
crucial role in the control of food intake (Turton et al., 1996).
GLP-1 signaling is among themost promising targets in the brain
for treating overeating disorders (Alhadeff et al., 2012; Dossat
et al., 2013; Drucker et al., 2008; Meeran et al., 1999; Secher
et al., 2014; Sisley et al., 2014). GLP-1 analogs have been
used to treat type 2 diabetes (for review, see Lovshin and
Drucker, 2009), and a GLP-1 receptor (GLP-1R) agonist, Sax-
enda (liraglutide), has recently been approved to treat obesity
(U.S. Food and Drug Administration, 2014). Central GLP-1 is
mainly secreted by a small group of neurons located within the
nucleus tractus solitarius (NTS) in the brainstem. GLP-1-ex-
pressing neurons project broadly to other brain regions including
the hypothalamus, the ventral tegmental area (VTA), and the nu-
cleus accumbens (NAc) (Gu et al., 2013). Accordingly, expres-
sion of GLP-1Rs has been detected in many brain areas, such726 Cell Reports 12, 726–733, August 4, 2015 ª2015 The Authorsas the VTA and NAc (Merchenthaler et al., 1999). Nevertheless,
it is still not fully understood how release of central GLP-1 within
the brain regulates food intake.
Regulatory mechanisms underlying the control of feeding may
bedivided into twocategories: homeostatic (i.e., hunger-induced
feeding to maintain energy balance) and reward-related (i.e., he-
donic or pleasure-driven acquisition of highly palatable food).
Feeding behavior is ultimately determined by a complex interac-
tion between the two (Liu et al., 2015). Hedonic eating has
become a key cause of weight gain and obesity. Therefore, there
is apressing need to further investigate the role of rewardcircuitry
in the regulation of feeding behavior (Volkow et al., 2011). The
neural circuits governing food intake intertwine with those medi-
ating reward, and the midbrain dopamine (DA) system has been
suggested toplay apivotal role in the regulation of reward-related
behaviors, including eating (Liu et al., 2015; Volkow et al., 2011).
Several studies report that pharmacologic manipulations of
GLP-1 signaling, i.e., using GLP-1 analog Exendin-4 (Exn4) or
GLP-1R blocker Exendin-9 (Exn9) infusions, in the VTA (Dickson
et al., 2012; Mietlicki-Baase et al., 2013), NAc (Alhadeff et al.,
2012; Dossat et al., 2011, 2013), NTS (Alhadeff and Grill, 2014),
and hippocampus (Hsu et al., 2015), affect the appetitive and
motivational aspects of feeding. Together, these findings sug-
gest that GLP-1 signalingmay affect hedonic food intake. Never-
theless, the neural basis of such effects remains enigmatic.
Utilizing chemogenetic tools, we demonstrated that endoge-
nously released GLP-1 from the NTS is sufficient to suppress
high-fat (HF) food intake. More specifically, we found that activa-
tion of NTS-originating GLP-1 nerve terminals in the VTA is suffi-
cient to suppress HF food intake. Furthermore, we uncovered
thatGLP-1R activation directly impedes excitatory synaptic drive
onto VTA-to-NAc medial shell projecting DA neurons. Thus,
GLP-1 released from NTS neurons may reduce highly palatable
food intake through suppression of mesolimbic DA signaling.RESULTS
Chemogenetic Activation of GLP-1-Expressing Neurons
Suppresses Food Intake
To precisely target GLP-1-expressing neurons in the NTS,
we took advantage of paired-like homeobox 2b (Phox2b)-Cre
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Figure 1. Activation of NTS GLP-1 Neurons
Releases GLP-1 and Reduces High-Fat
Diet Intake
(A and B) A representative sagittal mouse brain
section showing viral infection of NTS neuronswith
Cre-dependent AAV-DIO-channelrhodopsin-YFP
in Phox2b-Cre mice.
(C) Illustration depicts Phox2b-Cre animals in-
jected with AAV DIO-DREADDs (hM3Dq) and
timeline of experiments (D–F).
(D) Normalized high-fat (HF) diet intake measured
5 hr after i.p. injection of either PBS (control/re-
covery) or CNO. There was an overall time effect
(p < 0.05) and time3 group effect (p < 0.001); post
hoc t tests were used for comparison of individual
time points.
(E) Normalized HF diet intake at 5 hr during the
CNO i.p.-injection period only (mCherry n = 7,
hM3Dq n = 7, hM4Di n = 6). Average HF diet intake
over 3 days of CNO application was normalized to
the averages of the baseline (5 days). Absolute
food intake amount in different groups at different
times is shown in Figure S2. Student’s t tests were
used.
(F) HF diet intake suppression induced by hM3Dq
activation is blocked by the specific GLP-1 re-
ceptor antagonist Exendin-9 (Exn9) (mCherry n =
7; hM3Dq n = 6; Exn9 n = 6). Exn9 was applied
15 min before the application of CNO. There was
an overall time effect (p < 0.001), group effect (p < 0.001), and time3 group effect (p < 0.001); ANOVA 2 hr p < 0.001; post hoc Bonferroni: mCherry versus hM3Dq
p < 0.001; mCherry versus hM3Dq + Exn9 p = 0.051; hM3Dq versus hM3Dq + Exn9, p = 0.002. ANOVA 5 hr: p < 0.001; post hoc Bonferroni: mCherry versus
hM3Dq: p < 0.001, mCherry versus hM3Dq + Exn9: p = 0.227, hM3Dq versus hM3Dq + Exn9: p = 0.002.
All values represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001bacterial artificial chromosome (BAC) transgenicmice, which ex-
press Cre recombinase in GLP-1-containing neurons within
the NTS (Scott et al., 2011). Adeno-associated virus (AAV) ex-
pressing Cre-activated yellow fluorescent protein (YFP) was
injected into the NTS of Phox2b-Cre animals to specifically visu-
alize GLP-1 neurons (Figures 1A, 1B, and S1).We employed che-
mogenetics to address whether the activation of NTS GLP-1
neurons affects food intake by expressing designer receptors
exclusively activated by designer drugs (DREADDs). Specif-
ically, we expressed Cre-activated hM3Dq or hM4Di DREADDs
in the NTS of Phox2b-Cre mice through local stereotactic injec-
tions of AAVs. Upon binding to clozapine-N-oxide (CNO), a
synthetic agonist of DREADDs, Gq-coupled hM3Dq activates
neuronal burst firing while Gi-coupled hM4Di inhibits neuronal
firing (Sternson and Roth, 2014). By genetically encoding these
designer receptors into GLP-1 neurons in the NTS (Figures
S1B–S1D), we were able to control the activity of these neurons
in a temporal and spatial manner and evaluate the subsequent
impact on feeding behavior.
Immunostaining showed that neurons in the NTS expressing
these DREADDs or YFP also express GLP-1 (Figure S1). To
assay food-intake behavior, animals were given ad libitum ac-
cess to both standard rodent chow and a highly palatable HF
diet (Van Heek et al., 1997). Daily food intake was measured
for 5 days before performing chemogenetic experiments, in or-
der to establish a stable baseline of food consumption, and
intraperitoneal (i.p.) CNO injections were then performed for 3
consecutive days as experimental trials (Figures 1C and 1D).Activation of NTS GLP-1 neurons by CNO in Gq-coupled
hM3Dq-expressing animals led to significant decreases in HF
food intake compared to control mice expressing mCherry
alone (Figures 1D and 1E). Interestingly, the same procedure
showed little effect on standard chow intake (Figures S2A–
S2C). This is in contrast to the behavior induced by pharmaco-
logical activation of GLP-1 receptors by Exn4 (Alhadeff et al.,
2012). The activation of NTS GLP-1 neurons had little impact
on body weight within 24 hr after application of CNO (Fig-
ure S2D), which is consistent with results from deletion of
neuronal GLP-1Rs (Sisley et al., 2014). Conversely, hM4Di-ex-
pressing mice showed increased HF food intake (Figures 1E,
S2, and S3), suggesting that inhibition of NTS GLP-1 neurons
can facilitate food intake.
To unequivocally define the specific involvement of GLP-1
signaling in the suppression of HF food intake, we pre-admin-
istered GLP-1R antagonist Exn9 before the application of
CNO in a subset of hM3Dq-expressing animals. Remarkably,
we found that the food intake suppression induced by CNO
activation of hM3Dq receptors was blocked, indicating that
appetite suppression was specifically achieved by activating
GLP-1 release from hM3Dq-expressing NTS neurons (Fig-
ure 1F). The terminals of NTS GLP-1 neurons projecting to
VTA express vGluT2 (Zheng et al., 2014), but not vGluT1 (Fig-
ure S4A); thus, they may also release glutamate. However, our
data provide strong evidence that endogenous GLP-1
released from NTS neurons projecting to the VTA suppresses
food intake.Cell Reports 12, 726–733, August 4, 2015 ª2015 The Authors 727
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Figure 2. Activation of VTA GLP-1 Nerve
Terminals Reduces HF Diet Intake
(A) Illustration showing the injection of Exn4 directly
into VTA.
(B) Food intake at 2 hr, 5 hr, and 24 hr after bilateral
microinjections of PBS (n = 5) or Exendin-4 (Exn4,
n = 5) into the VTA of wild-type mice. Repeated
measurement: time, p < 0.001; group, p < 0.001;
time 3 group, p < 0.001.
(C) NTS axons visible in VTA region immunostained
for tyrosine hydroxylase (TH).
(D) Illustration showing the injection of AAV DIO-
DREADDs into the NTS region of Phox2b-Cre an-
imals and CNO infusion into VTA brain region of
AAV-injected animals.
(E) Plot of HF diet intake from hM3Dq mice after
injection of CNO in VTA compared to control levels
of HF diet intake that were measured 1 day prior to
injections. There was an overall time effect (p <
0.001) and time 3 group effect (p < 0.001).
(F) HF diet intake 5 hr after injection of CNO into
VTA in mice expressing mCherry (n = 8), hM3Dq
(n = 7), or hM4Di (n = 7). Student’s t tests were
used. All values represent mean ± SEM. *p < 0.05,
***p < 0.001. Post hoc t tests were used.GLP-1 Release in the VTA Regulates HF Food Intake
Next, we asked whether GLP-1 signaling within the mesolimbic
system is involved in regulating HF food intake. Consistent with
previous reports (Dickson et al., 2012; Mietlicki-Baase et al.,
2013),wedemonstrated that intra-VTA infusionof Exn4produced
profound HF food intake suppression relative to control animals
undergoing saline injections (Figures 2A and 2B). Therefore, we
speculated that the VTA is a critical component of the neural cir-
cuitry through which GLP-1 controls reward-driven food intake.
Next, we sought to use DREADDs to induce the release of GLP-
1 from thenerve terminals. The hM3Dq is aGq-coupledDREADD,
and its activation stimulates the production of inositol triphos-
phate and diacylglycerol (Pei et al., 2008), both of which are
known to increase synaptic vesicle release at the nerve terminal
(Nakamura et al., 1999; Rhee et al., 2002). We injected CNO
directly into the VTA of hM3Dq-mCherry-, hM4Di-mCherry-, and
mCherry-expressing mice (Figure S4B), and we observed
whether CNO altered food intake behavior. Interestingly, consis-
tent with results from microinjections of Exn4 into the VTA (Fig-
ure 2B), local chemogenetic activation of GLP-1 nerve terminals
in the VTA in hM3Dq-expressing mice significantly suppressed
HF food intake (Figures2C–2F).Wecannot exclude thepossibility
that action potentials generated by CNO at the nerve terminals
might back propagate to the cell body and then possibly release
GLP-1 inotherbrain regions.However, ourdata suggest that sup-
pression of food intake by hM3Dq and CNO is at least partially
mediated by locally released GLP-1. Infusion of CNO into the
VTA did not produce altered feeding behavior in hM4Di-express-
ing mice (Figures S4C and S4D), suggesting that dampening
GLP-1 signaling in the VTA alone may not be sufficient to induce
the acute overeating response observed after broader suppres-
sion of all GLP-1 neurons by i.p. injections of CNO (Figure 1E).728 Cell Reports 12, 726–733, August 4, 2015 ª2015 The AuthorsOur data therefore demonstrate that local activation of NTS pro-
jections in the VTA is likely sufficient to decrease HF food intake,
supporting the hypothesis that central GLP-1 release can regu-
late feeding behavior via signaling pathways within the reward
centers of the brain.
GLP-1R Activation Suppresses Excitatory Synaptic
Inputs onto the VTA-to-NAc-Projecting DA Neurons
Given that synaptic transmission and plasticity govern informa-
tion flow in the brain and control behavioral outcomes, we
hypothesized that GLP-1 signaling modulates synaptic trans-
mission in the mesolimbic system. We focused on the modula-
tory effects of GLP-1 in VTA-to-NAc medial-shell-projecting
neurons, which compose a well-established reward pathway
(Lammel et al., 2011, 2012). To identify these neurons, we in-
jected retrograde fluorescent microbeads into the NAc medial
shell (Figure 3A). The majority of VTA-to-NAc-projecting neurons
were DA, as shown by detection of tyrosine hydroxylase (TH)
by immunohistochemistry (IHC) (Figure 3A). In order to study
morphologic and electrophysiologic properties of these neu-
rons, we performed whole-cell patch-clamp recordings. We
included fluorescent dye (either Alexa 594-dextran or Alexa
488-biocytin) for filling the recorded cells. Neuronal subtypes
were identified by post hoc IHC for TH (Figures 3B and 3C).
We found that TH+ DA VTA neurons have more dendritic branch-
ings, smaller N-methyl-D-aspartate (NMDA)-receptor-mediated
excitatory postsynaptic currents (EPSCs), and a higher ratio
of a-amino-3-hydroxy-5- methyl-4-isoxazolepropionic acid
(AMPA) receptor to NMDA-receptor-mediated EPSCs (i.e.,
AMPA/NMDA EPSC ratio) (Figure S5). Nevertheless, we found
no clear differences in the sizes of hyperpolarization activated
cation channel mediated currents (Ih) (Figure S5A) between
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Figure 3. Exendin-4 Suppresses Excitatory
Synaptic Strength of VTA-to-NAc-Projec-
ting DA Neurons
(A) Schematic illustration of stereotaxic injection of
fluorescent microbeads in NAc (left). Representa-
tive image of NAc injection site (middle panel).
Statistical distribution of TH+ and TH VTA-to-NAc
medial-shell-projecting neurons (right).
(B) Confocal images of recorded retrograde
labeled neurons in VTA that were labeled with
Alexa Fluor 594 and post hoc immunostained for
tyrosine hydroxylase (TH).
(C) Representative confocal image of a non-DA
(TH) VTA-to-NAc-projecting neuron. Green, mi-
crobeads; red, Alexa Fluor 594; blue, TH.
(D) Sample AMPAR and NMDAR response
at +40 mV from DA VTA-to-NAc neurons before
(red) and after (black) bath application of Exendin-
4 (Exn4).
(E–H) Statistical results of AMPAR (E), NMDAR (F),
AMPAR/NMDAR (G), and coefficient of variation
(H) from evoked recordings of TH+ VTA-to-NAc-
projecting neurons (n = 13).
(I) Sample AMPAR and NMDAR response
at +40 mV from non-DA (TH) VTA-to-NAc neu-
rons before (blue) and after (black) bath application
of Exn4.
(J–M) Statistical results of AMPAR (J), NMDAR (K),
AMPAR/NMDAR (L), and coefficient of variation
(M) from evoked response recordings of non DA
VTA-to-NAc-projection neurons (n = 7).
All values represent mean ± SEM. Note that paired
t tests were used to define statistical significance.
*p < 0.05, **p < 0.01.TH+ and TH VTA-to-NAc-projecting neurons. The sizes of Ih
have been used for electrophysiologic identification of the VTA
DA neurons (Chieng et al., 2011). However, these data suggest
that categorizing VTA neurons as DA or non-DA by measuring
Ih current alone may not be adequate, as described previously
(Ungless and Grace, 2012).
To test whether GLP-1R activation regulates synaptic plas-
ticity within the VTA, we recorded EPSCs in VTA-to-NAc
medial-shell-projecting neurons in the absence or presence of
GLP-1R agonist Exn4 (Figures 3, 4, and 5). Neuronal subtypes
were identified by post hoc IHC for TH. In TH+ VTA-to-NAc pro-
jecting neurons, application of Exn4 consistently suppressed
AMPA-receptor-mediated EPSCs (Figures 3D and 3E). However,
no significant change was found in NMDA EPSCs before and
after Exn4 application (Figure 3F). These data suggest that post-
synaptic modifications reduce the excitatory synaptic strength,
most likely through the specific removal of AMPA receptorsCell Reports 12, 726–73from the postsynaptic membrane (other-
wise, NMDA-receptor-mediated EPSCs
would additionally show a reduction after
Exn4 application). We then measured the
AMPA/NMDA EPSC ratio, which sug-
gested modifications in synaptic strength
by the insertion or removal of AMPA re-
ceptors during long-term synaptic plas-ticity. We found a consistent reduction in the AMPA/NMDA
EPSC ratio after the application of Exn4 (Figure 3G), further sug-
gesting a postsynaptic modification.
In order to further delineate the pre- and post-synaptic mech-
anisms, we first calculated the coefficient of variation of evoked
AMPA-receptor-mediated EPSCs, which showed no significant
change with application of Exn4, suggesting no obvious alter-
ation in presynaptic release probability. Moreover, we also
recorded miniature EPSCs (mEPSCs) in the presence of tetro-
dotoxin (TTX) and found that the amplitude in DA neurons
significantly decreased following application of Exn4 (Figures
4A–4C). Additionally, the paired-pulse ratio of evoked EPSCs
showed no obvious change before or after Exn4 application
(Figures S5I and S5J), again suggesting unaltered presynaptic
vesicle release probability.
In contrast, in TH (non-DA) VTA-to-NAc-projecting neurons,
the application of Exn4 produced minor changes in AMPA- and3, August 4, 2015 ª2015 The Authors 729
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Figure 4. Exendin-4 Regulates Miniature
Synaptic Release at Excitatory Synapses in
VTA-to-NAc Projection Neurons
(A) Sample traces of mEPSCs recorded from DA
VTA-to-NAc-projecting neurons before (red) and
after (black) bath application of Exendin-4 (Exn4).
(B and C) Frequency (B) and amplitude (C) of
mEPSCs in VTA-to-NAc-projecting DA neurons
(n = 9).
(D) Sample recordings of mEPSCs in non-DA
neurons before and after Exn4 application.
(E and F) Frequency (E) and amplitude (F) of
mEPSCs in non-DA VTA-to-NAc-projecting neu-
rons (n = 5).
All values represent mean ± SEM. Note that paired
t tests were used to define statistical significance.
**p < 0.01.NMDA-receptor-mediated evoked EPSCs, a moderate increase
in the AMPA/NMDA ratio (in contrast to the decrease in TH+ neu-
rons), and no change in the coefficient of variance of EPSCs (Fig-
ures 3C and 3I–3M). Moreover, we did not observe changes in
mEPSCs in non-DA neurons (Figures 4D–4F). Together with the
data from VTA-to-NAc-projecting DA neurons, these data sug-
gest a cell-type-specific effect of GLP-1R activation on synaptic
plasticity in the VTA.
Considering that neurons in the VTA also receive inhibitory
synaptic inputs that are mediated by GABA (Johnson and
North, 1992), we also studied the regulatory effects of GLP-1R
activation on inhibitory synaptic inputs onto VTA-to-NAc
medial-shell-projecting neurons. Activation of GLP-1Rs by
Exn4 resulted in an increase in the amplitude of spontaneous
inhibitory postsynaptic currents (sIPSCs) in DA VTA neurons
(Figures 5A–5D). In contrast, GLP-1R activation had no obvious
impact on sIPSCs in non-DA neurons (Figures 5E–5H). Further-
more, no significant differences were detected in miniature
inhibitory postsynaptic currents (mIPSCs) in the presence of
TTX (Figures 5I and 5J). Thus, Exn4 may facilitate inhibitory syn-
aptic transmission mediated by spontaneous action potentials in
the VTA-to-NAc-projecting DA neurons.
DISCUSSION
This study demonstrates that release of endogenousGLP-1 from
NTS neurons projecting to the VTA is sufficient to reduce highly
palatable food intake in mice. Moreover, we identified that
excitatory synaptic drive onto VTA DA neurons projecting to
the medial shell of the NAc is specifically suppressed upon
GLP-1R activation, implying a downregulation of VTA-to-NAc
DA signaling.
GLP-1 receptors are broadly expressed in the brain including
the hypothalamus and reward centers such as the NAc and
VTA (Merchenthaler et al., 1999). Food intake can be regulated
by homeostatic (hunger-driven) signals and hedonic (reward-
related) signals, and the mesolimbic DA system is a common
neural integrator involved in hedonic food intake control (Kenny,730 Cell Reports 12, 726–733, August 4, 2015 ª2015 The Authors2011; Volkow et al., 2011). Exogenous application of GLP-1
analogs in the VTA suppresses food intake (Dickson et al.,
2012; Mietlicki-Baase et al., 2013). Consistent with these obser-
vations, our data show that exogenous application of GLP-1R
agonist Exn-4 in the VTA is sufficient to reduce consumption of
HF food. We also demonstrate that endogenously released
GLP-1 in the VTA is sufficient to reduce HF food intake (Figure 1).
We thus propose that endogenous GLP-1 signaling within the
mesolimbic system may be an effective target to manipulate
eating behavior.
The mechanisms underlying GLP-1-mediated food-intake
suppression are not fully understood. Limited reports on the
role of GLP-1 in regulating synaptic function show that GLP-1R
activation increases firing in hypothalamic orexin/hypocretin
neurons by regulating intrinsic membrane properties (e.g., so-
dium and calcium channel conductance and spontaneous
neurotransmitter release) (Acuna-Goycolea and van den Pol,
2004). In pancreatic-projecting neurons in the brainstem,
GLP-1 has been shown to facilitate sEPSC and sIPSC release
(Wan et al., 2007). Our data indicate that GLP-1 analog Exn4
regulates synaptic transmission in a cell-type-specific and
synapse-specific manner. Among the VTA-to-NAc medial-
shell-projecting neurons, DA neurons show a decrease in excit-
atory synaptic strength and a facilitation of inhibitory synaptic
inputs upon administration of Exn4 (Figures 3 and 5). However,
non-DA neurons show increased excitatory synaptic strength
(without perturbed inhibitory synaptic strength) upon GLP-1R
activation (Figures 4 and 5).
Unequivocal identification of the specific pathways (e.g., VTA
to NAc) and cell types (e.g., DA versus non-DA neurons) is partic-
ularly important for interpreting functional information in the
VTA, because (1) previous identification of DA neurons within
the VTA based on electrophysiological characteristics remains
controversial (Ungless and Grace, 2012) and (2) VTA DA neurons
projecting to the NAc or prefrontal cortical brain regions have
differential responses toward reward and aversion (Lammel
et al., 2011, 2012). Our data support this complexity, although
they somewhat contradict results from a previous report
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Figure 5. Effects of Exendin-4 on VTA-to-
NAc-Projecting Neuron Response to Inhibi-
tory Inputs
(A) Sample recordings of TH+ neurons before and
after bath application of Exendin-4 (Exn4).
(B) Confocal images of a representative TH+ VTA-
to-NAc-projecting recorded neuron labeled with
microbeads from NAc (upper left) and Alexa 488-
biocytin from a recording electrode (upper right)
and immunostained for tyrosine hydroxylase (TH;
lower left).
(C) sIPSC amplitude of TH+ VTA-to-NAc-projec-
ting neurons before (white) and after (pink shaded
area) bath application Exn4; top trace shows the
average trace of events before (red) and after
(black) application of Exn4.
(D) Statistical results of sIPSC recordings from (A)
(n = 8).
(E) Sample recordings of TH neurons before and
after bath application of Exn4.
(F) Confocal images of representative TH VTA-
to-NAc-projecting neurons recorded that were
labeled with retrobeads from NAc (upper left)
and Alexa 488-biocytin from recording electrode
(upper right) and immunostained for tyrosine
hydroxylase (TH, lower left).
(G) sIPSCs amplitude of TH VTA-to-NAc-projec-
ting neurons before (white) and after (pink shaded
area) bath application of Exn4; top trace shows the
average trace of events before and after applica-
tion of Exn4.
(H) Statistical results of sIPSC recordings from (E)
(n = 5).
(I and J) Impact of Exn4 on mIPSCs in TH+ VTA-to-
NAc-projecting neurons (I) and TH VTA-to-NAc-
projecting neurons (J). Shown are representative
traces before and after Exn4 (left) and pooled data
of average frequencies and amplitudes of mIPSCs
(n = 5 in both groups) (right).
Data are presented as mean ± SEM. Note
that paired t tests were used to define statistical
significance. **p < 0.01.showing facilitation of excitatory synaptic transmission by Exn4
in putative DA neurons identified by the sizes of Ih current in the
rat VTA (Mietlicki-Baase et al., 2013). The discrepancy could
arise from differences in neuronal subtypes, given that as
mentioned previously, electrophysiology may not be a reliable
method for identifying DA VTA neurons and projection pathways
were not defined. Of course, species differences may also exist.
Within the core of the NAc, GLP-1Rs seem to have no regula-
tory effect on DA nerve terminals, because application of Exn4
appears to not alter DA release in striatal brain slices lackingCell Reports 12, 726–73midbrain cell bodies (Mietlicki-Baase
et al., 2014). These data simply indicate
that GLP-1R signaling in the NAc core
does not involve local regulation of DA
release and are not at all contradictory
to our hypothesis that DA released
by VTA-to-NAc-projecting neurons func-
tions to reduce appetite by decreasingpleasure and reward derived from palatable food. Support for
this hypothesis was provided by a recent study in humans
demonstrating that DA enhances the neural reward response
to food, thereby influencing food-intake behavior (Medic et al.,
2014). We thus hypothesize that endogenous release of central
GLP-1 suppresses mesolimbic DA signaling and reduces
appetite by decreasing the pleasure and reward derived from
palatable food.
We show evidence that excitatory input to VTA-to-NAc
medial-shell-projecting DA neurons is reduced, implying3, August 4, 2015 ª2015 The Authors 731
decreased release of DA into the NAc. In exploring the relation-
ships among food intake, GLP-1 signaling, and synaptic trans-
mission within the reward neural circuitry, we provide an
integrated perspective that likely has implications for other moti-
vated behaviors, such as drug abuse and addiction (Egecioglu
et al., 2013; Shirazi et al., 2013). Further studies examining other
brain regions, circuits, and cell types, as well as the underlying
molecular mechanisms, are needed to comprehensively under-
stand the role of GLP-1 in regulating food intake and other
reward-driven behaviors.
EXPERIMENTAL PROCEDURES
Animals
All procedures involved using mice were approved by the Rutgers Robert
Wood Johnson Medical School Institutional Animal Care and Use Committee.
The Phox2b-Cre mice (Scott et al., 2011) were obtained from The Jackson
Laboratory (stock 016223). Wild-type mice (C57/Bl6) were purchased from
The Jackson Laboratory.
AAV Infection of NTS Neurons
Under isoflurane inhalation anesthesia (VetEquip) and using a stereotaxic in-
strument (KOPF M1900), Phox2b-Cre mice were injected bilaterally (0.6–1 ml
each side) in the NTS (lambda 3.15 mm; lateral ±0.6 mm; ventral 4.15 mm)
with either AAV-hSyn-DIO-hM4Di-mCherry, AAV-hSyn-DIO-hM3Dq-mCherry,
AAV-hSyn-DIO-mCherry, or AAV-DIO-ChR-YFP (UNC GTC Vector Core).
The ChR-YFP is membrane-bound and allows for detailed morphological an-
alyses of both the cell bodies and axons of Cre-expressing neurons.Mice were
allowed a survival period of 14 days prior to experimental manipulation. Injec-
tions sites were confirmed in all animals.
IHC
Mice were anesthetized with euthasol and transcardially perfused with 4%
paraformaldehyde (PFA) in PBS (pH 7.4). Either coronal or sagittal brain slices
(50 mm) were prepared, and a standard IHC protocol was followed. The pri-
mary antibodies used were TH (affinity-purified rabbit anti-tyrosine hydroxy-
lase 1:1,000; Abcam), vGluT1 (mouse monoclonal 1:1,000; Abcam), vGluT2
(NeuroMab), and GLP-1 (affinity-purified chicken anti-GLP-1, peptide se-
quences HAEGTFTSDVSSYC, or Peninsula Laboratories T-4363). Alexa Fluor
secondary antibodies used to visualize the signal using a confocal micro-
scope. For slice physiology post hoc immunostaining, brain slices were fixed
in 4% PFA for 2 hr, then washed in PBS and processed with IHC.
Behavioral Test
Mice (7–8 weeks old) were housed on a 12-hr light (06:00)/dark (18:00) cycle
with ad libitum access to water, standard chow (fat 21.635% mouse diet 20,
LabDiet), and HF diet (45 kcal% fat, Research Diet) in all behavioral experi-
ments. Note that when mice were given a standard chow and HF diet, the
animals would mainly consume the HF diet. Prior to experiments, animals
were housed in individual cages for 3 days. All i.p. and stereotaxic injections
with Exn4 (Tocris, 2.4 mg/kg, i.p. and 0.24 mg/kg for intracranial)/0.9% saline
or CNO (0.3 mg/kg, 100 ml, i.p. and 0.03 mg/kg, 50 ml each side, for intracra-
nial)/0.9% saline were performed at the beginning of the dark cycle (start
time 18:00 hr). For assaying the involvement of GLP1-R in food intake suppres-
sion by NTS GLP1 neuronal activation using chemogenetics, Exn9 (8.4 mg/kg)
was injected i.p.15 min prior to i.p. injection of CNO. Exn4, Exn9, and CNO
(Tocris) were stored in aliquots at20Canddissolved in vehicle (0.9%sodium
chloride) before use. Food weight was measured at 18:00, 20:00, 23:00, and
06:00 to calculate food intake volume. Intake was adjusted for spillage.
Retrograde Labeling of VTA-to-NAc Medial-Shell-Projecting
Neurons
Mice (6 weeks old) were anesthetized using isoflurane, placed into a stereotac-
tic frame (KOPF M1900), and red or green RetroBeads (100 nl; LumaFluor)
were injected bilaterally in the medial shell region of the NAc (bregma732 Cell Reports 12, 726–733, August 4, 2015 ª2015 The Authors2.2 mm; lateral ±0.5 mm; ventral 4.5 mm). To allow adequate time for retro-
grade transport of the RetroBeads to the somata of VTA neurons, mice were
allowed to survive for 14 days prior to slice physiology. Injections sites were
confirmed in all animals.
Electrophysiological Recordings from Adult Mouse Midbrain
Electrophysiology was performed as described previously (Pang et al., 2002)
with modifications. Briefly, mice were deeply anesthetized with Euthasol.
Coronal midbrain slices (300 mm) were prepared and whole-cell patch-clamp
recordings were done at 30C. Patch pipettes (3.8–4.4 MU) were pulled from
borosilicate glass and filled with internal solution containing 40 mM CsCl,
10 mM HEPES, 0.05 mM EGTA, 1.8 mM NaCl, 3.5 mM KCl, 1.7 mM MgCl2,
2 mM Mg-ATP, 0.4 mM Na4-GTP, 10 mM phosphocreatine, and 5 mM
QX-314. Alexa Fluor 594 (Life Technologies) or 0.2% Neurobiotine-488
(Life Technologies) was added to label recorded neurons (pH 7.2; 280–290
mOsm). Whole-cell patch-clamp recordings were done using Axon 700B
amplifier. Data were filtered at 2 kHz, digitized at 10 kHz, and collected using
Clampex 10.2 (Molecular Devices). To record EPSCs, picrotoxin (50 mM,
Sigma-Aldrich) was added to block IPSCs mediated by GABAA receptors.
TTX (1 mM) was added to block action potential for mEPSCs recording. To
record inhibitory currents, the NMDAR antagonist D-APV (50 mM) and the
AMPAR antagonist CNQX (20 mM) were added to block excitatory currents.
A bipolar stimulating electrode was placed 100–300 mm lateral to the recording
electrode and used to stimulate afferents at 0.05 Hz. Neurons were voltage-
clamped at 70 mV to record AMPAR EPSCs or IPSCs and at +40 mV to
record dual-component EPSCs containing NMDAR EPSCs. AMPAR/NMDAR
ratios were also calculated by dividing the peak of the AMPAR EPSC at
70 mV by the value of the NMDAR EPSC after stimulation start time 50 ms
at +40 mV.
Data Analysis
Repeated-measures ANOVA and multiple t test with Bonferroni were used.
Student’s t test or paired t test were used to determine statistical differences.
Two-way ANOVA analysis was used for multiple treatments with multiple
groups. Statistical significance was set at p < 0.05. All data values are pre-
sented as means ± SEM.
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